Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report)’s share price was down 4.1% on Thursday . The stock traded as low as $3.27 and last traded at $3.30. Approximately 72,044 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 312,790 shares. The stock had previously closed at $3.44.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Lexaria Bioscience in a report on Thursday, July 18th.
Get Our Latest Research Report on LEXX
Lexaria Bioscience Trading Down 5.2 %
Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last released its quarterly earnings data on Friday, July 12th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.04). The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.15 million. As a group, sell-side analysts forecast that Lexaria Bioscience Corp. will post -0.42 EPS for the current fiscal year.
Institutional Investors Weigh In On Lexaria Bioscience
A number of institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC acquired a new stake in Lexaria Bioscience during the second quarter worth about $63,000. Welch Group LLC acquired a new stake in shares of Lexaria Bioscience during the 1st quarter worth approximately $87,000. Cowen AND Company LLC bought a new position in Lexaria Bioscience in the fourth quarter valued at approximately $320,000. Finally, Armistice Capital LLC acquired a new position in Lexaria Bioscience during the second quarter valued at approximately $2,836,000. Institutional investors own 13.06% of the company’s stock.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
Featured Stories
- Five stocks we like better than Lexaria Bioscience
- What Are the FAANG Stocks and Are They Good Investments?
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- Investing in the High PE Growth Stocks
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Insider Trading – What You Need to Know
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.